Published in
Taylor and Francis Group, Expert Opinion on Therapeutic Targets, 4(20), p. 393-405, 2016
DOI: 10.1517/14728222.2016.1151002
Links
- Taylor and Francis Group | PDF
- ORCID
- [www.research.ed.ac.uk] | PDF
- [www.pure.ed.ac.uk] | PDF
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance
Journal article published in 2016 by
Laura Garros-Regulez,
Paula Aldaz,
Olatz Arrizabalaga,
Veronica Moncho-Amor,
Estefania Carrasco-Garcia,
Lorea Manterola,
Leire Moreno-Cugnon 
,
Cristina Barrena,
Jorge Villanua,
Irune Ruiz,
Steven Pollard,
Robin Lovell-Badge,
Nicolas Sampron,
Idoia Garcia,
Ander Matheu
,
Cristina Barrena,
Jorge Villanua,
Irune Ruiz,
Steven Pollard,
Robin Lovell-Badge,
Nicolas Sampron,
Idoia Garcia,
Ander Matheu
This paper is available in a repository.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 